ATANIS Biotech AG

ATANIS Biotech AG has been incorporated as a spin-off company from the University of Bern by the four co-founders Mrs. Noemi Zbären, Prof. Thomas Kaufmann, Prof. Alexander Eggel and Prof. Jean-Pierre Kinet in Summer 2021. The company has developed a novel functional cell based assay that massively simplifies the diagnosis of allergies and can predict treatment success of therapies. This test will additionally be used to assess safety and efficacy of potential new drug candidates for allergy treatment as well as for the evaluation of allergenicity of various food products. The proprietary assay is offered through a fee-for-service business model to our customers all over the world.